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Since the Pap test was introduced in the 1940s, there has been an approximately 70% reduction in the incidence of squamous
cell cervical cancers in many developed countries by the application of organized and opportunistic screening programs. The
eﬃcacy of the Pap test, however, is hampered by high interobserver variability and high false-negative and false-positive rates. The
use of biomarkers has demonstrated the ability to overcome these issues, leading to improved positive predictive value of cervical
screeningresults.Inaddition,theintroductionofHPVprimaryscreeningprogramswillnecessitatetheuseofafollow-uptestwith
high speciﬁcity to triage the high number of HPV-positive tests. This paper will focus on protein biomarkers currently available for
use in cervical cancer screening, which appear to improve the detection of women at greatest risk for developing cervical cancer,
including Ki-67, p16INK4a,B DP r o E xC ,a n dC y t o a c t i vH P VL 1 .
1.Introduction
Cervical cancer is the second most common cancer in
women worldwide and remains a major cause of morbidity
andmortality.SincethePaptestwasintroducedinthe1940s,
there has been an approximately 70% reduction in the inci-
d e n c eo fs q u a m o u sc e l lc e r v i c a lc a n c e r si nm a n yd e v e l o p e d
countries by the application of organized and opportunistic
screening programs. The eﬃcacy of the Pap test, however, is
hampered by high interobserver variability and high false-
negative and false-positive rates [1–3]. However, as cervical
cancer evolves through well-deﬁned noninvasive intraep-
ithelial stages, which can be distinguished morphologically,
repeated screening at frequent intervals can maintain high
levels of protection.
Investigators have attempted by various means to
enhance the sensitivity of the Pap test. First by the introduc-
tion of liquid-based methods to address issues of specimen
collection and preparation, and later by the use of computer-
assisted screening systems to address screening errors and to
improve screening eﬃciency and disease detection. Testing
for oncogenic, high-risk human papillomavirus (hrHPV)
DNA has been accepted as an adjunct to borderline/ASC-
US cytology in primary screening. The utility of HPV as a
reﬂex test within the ASC-US patient population is largely
reﬂected in its negative predictive value (NPV), where an
HPV negative result indicates a low likelihood of ﬁnding
CIN2+ lesions upon colposcopy [4]. This triage application,
however, has a very low speciﬁcity and correspondingly low
positive predictive value for ﬁnding CIN2+ disease. Another
testing algorithm involving cytology and HPV cotesting
was reported to lead to earlier detection of CIN3+ lesions,
supporting a lengthening of the screening interval [5]. In
this cotesting algorithm, the combined use of cytology plus
HPV testing has a very high NPV. As such, it is useful
to screen a presumed normal and healthy population for2 Journal of Oncology
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Figure 1: Cell cycle alterations induced by HPV E6 and E7 oncogenes in cervical neoplasia, adapted from Malinowski [11]. The presence
of E7 disrupts G1-S phase regulation through the interference with E2F-Rb binding. P16INK40 is strongly expressed due to the loss of
Rb/E2F repression and the strong activation by free E2F. The release of E2F results in the increased transcription of S-phase genes, including
MCM2 and TOP2A. The interaction of E6 with p53 results in p53 ubiquitination and subsequent degradation, resulting in the abrogation
of apoptosis. The proliferation marker Ki-67 is increased in the presence of cell cycle dysregulation caused by the E6 and E7 oncogenes.
the presence of CIN2+ disease and to stratify patients into
two groups: (i) HPV negative, cytology normal patients
who are at low risk for developing CIN2+ disease and
thus qualify for an extended screening interval and (ii)
patients who are either cytology abnormal or HPV positive
and who are at increased risk for developing CIN2+ and
require more active surveillance. Most recently, the use
of hrHPV DNA detection as a primary screening test for
cervical disease has been investigated [6–10]. The majority
of hrHPV infections, however, induce low-grade precursor
lesions, which are cleared spontaneously within one to two
years of exposure, with less than 10% eventually progressing
to high-grade lesions or invasive cancer. Thus, while hrHPV
DNA testing has a very high sensitivity for the detection of
high-grade cervical disease, it has a very low speciﬁcity and
positive predictive value, thus would always require a follow-
up test prior to treatment to avoid unnecessarily raising
patient anxiety levels and referrals to invasive colposcopic
procedures.
The use of biomarkers in both cervical cytology and
histology has demonstrated the ability to overcome issues
with both false-positive and false-negative results, leading
to improved positive predictive value of cervical screening
results. Numerous protein biomarkers for the detection of
cervical disease have been identiﬁed. Many of these proteins
are involved in cell cycle regulation, signal transduction,
DNA replication, and cellular proliferation (reviewed in
[11–13]). The altered expression of these proteins is a
consequence of the binding of the high-risk HPV E6 and
E7 oncogenes to host regulatory proteins, resulting in the
degradation of the p53 tumor suppressor gene product and
the inactivation of the retinoblastoma protein leading to
dysregulation of the cell cycle (Figure 1).
In contrast to the cellular markers, the HPV L1 capsid
protein is a virus-speciﬁc protein and a major stimulus of the
immune system used within the HPV vaccines.
This paper will focus on protein biomarkers currently
under investigation for use in cervical cancer screening that
appear to improve the detection of women at greatest risk
for developing cervical cancer, including Ki-67, p16INK4a,
BD ProEx C, and Cytoactiv HPV L1. These biomarkers are
reportedtohavearoleinthetriageofindeterminatecytology
cases, discrimination of true high-grade cervical dysplasia
from mimics in histology, and may serve as predictive
markers to identify lesions most likely to progress to high-
gradecervicaldiseaseandcancer.Thestainingcharacteristics
and reported usage of the various biomarkers in cervical
cancer screening are summarized in Table 1.
2.Biomarkers Used inCervicalScreening
2.1.Ki-67. Ki-67isanuclearandnucleolarproteinexpressed
during the G1, S, G2, and M phase of the cell cycle, while not
being present in resting cells (G0 phase), and can, therefore,Journal of Oncology 3
Table 1: Biomarkers used in cervical cancer screening and diagnosis.
Biomarker Staining Cellular process detected Reported use of
biomarker
Pattern
Ki-67 Nuclear
Increased Ki-67 staining
reﬂects increased epithelial
cell proliferation found in
HPV-infected tissues.
(i) Measure of cell
proliferative capacity.
(ii) Recognizes tissues
involved by HPV and
extent of Ki-67
immunostaining
generally parallels
increasing grades of
dysplasia.
(iii) Predominantly used
in histology applications.
p16INK4a Nuclear and
cytoplasmic
p16 levels increased in
response to irregular cell
cycle inactivation resulting
from the disruption of
interaction of pRb with
transcription factor E2F in
the presence by the HPV
E7 oncogene.
(i) Detection can serve
as a surrogate biomarker
for persistent infection
with high-risk HPV.
(ii) Triage of equivocal
cytology ﬁndings can
facilitate identiﬁcation
of abnormal cells in
cytology preparations.
(iii) Aid in
interpretation of
histological material.
Limited evidence for use
as a predictor of disease
progression in histology
specimens.
BD ProEx C Nuclear
Increased cellular levels of
MCM2 and TOP2A due to
aberrant transcription of
S-phase proteins resulting
from the interaction of
HPV E6 and E7
oncoproteins with cell
cycle proteins p53 and Rb.
(i) Marker of cells with
proliferative capacity.
(ii) Triage from
abnormal cytology to
increase PPV over
cytology alone or HPV
triage for detection of
CIN2+ disease. Can also
facilitate identiﬁcation
of abnormal cells in
cytology preparations.
(iii) Use in histology to
distinguish true
dysplasia from mimics
such as
reactive/reparative
changes, immature
squamous metaplasia,
and atrophy.
Cytoactiv
HPV L1 Nuclear
HPV L1 capsid protein
found in mild-to-moderate
dysplasias, but lost in
higher-grade
intraepithelial neoplasias.
(i) Possible prognostic
marker to identify early
dysplastic lesions most
likely to progress to
high-grade disease.
provide an index of the cell growth fraction. While the
function of the Ki-67 protein remains unclear, its expression
appears to be an absolute requirement for progression
through the cell-division cycle [14, 15]. Since HPV infection
leads to increased epithelial cell proliferation in infected
tissues, increased Ki-67 staining can be an indicator of HPV
infection. In normal human cervical squamous mucosa,
expression of Ki-67 is limited to the proliferating basal and
parabasal cells. In dysplasia and carcinoma, however, expres-
sion extends above the basal one third of the epithelium4 Journal of Oncology
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Figure 2: Biomarker expression in low-grade squamous intraepithelial lesions and high-grade squamous intraepithelial lesions in cervical
cytology specimens. Ki-67, p16INK4a, BD ProEx C, and BD SurePath Plus expression detected in liquid-based cytology samples and Cytoactiv
HPV L1 staining performed on conventional Pap smears (L1 images courtesy of Dr. Ralf Hilfrich).
and the number of positive cells increase, with a signiﬁcant
positive correlation between ascending grade of squamous
intraepithelial lesion and labeling index (Figure 3)[ 16]. The
most commonly used antibody for immunohistochemical
detection of the Ki-67 antigen is clone MIB-1.
2.2. p16INK4a. The protein p16INK4a is a cell-cycle regulator,
with its expression tightly controlled in normal cells. This
tumor suppressor protein inhibits cycle-dependant kinases 4
and 6, which phosphorylate the retinoblastoma (Rb) protein
[17, 18]. Usually, binding of Rb to E2F blocks E2F-driven
cell cycle activation and entry into the S-phase of the cell
cycle. In a transforming HPV infection, however, the viral
oncogene E7 disrupts the binding of the Rb protein to the
E2F transcription factor, resulting in drastically increased
levels of p16INK4a [19, 20], the detection of which can serve
as a surrogate biomarker for persistent infection with high-
risk HPV (Figure 1). It is widely accepted that p16INK4a is a
sensitive and speciﬁc marker of dysplastic cells of the cervix
and is a useful biomarker in cervical cancer lesion diagnosis
and cervical screening [21–25]. Multiple antibodies to p16
have been utilized in research studies; however, the E6H4
clone (CINtec, mtm laboratories AG, Heidelberg, Germany)
appears to be most commonly used. A dual p16/Ki-67
immunocytochemistry assay is now also available for use as
an adjunctive test in cervical cancer screening (CINtec Plus,
mtm laboratories AG, Heidelberg, Germany).
2.3. BD ProEx C. BD ProEx C is a protein-based biomarker
reagent (BD Diagnostics, Burlington, NC, USA) containing
antibodies to the nuclear proteins minichromosome main-
tenance protein 2 (MCM 2) and topoisomerase II alpha
(TOP2A), proteins that have been shown to accumulate in
HPV-transformedcells.BDProExCstainingislimitedtothe
basal proliferating layer of normal cervical epithelium and
is absent in diﬀerentiated and quiescent cells. In contrast,
in cervical glandular and squamous dysplasia, BD ProEx C
expression is dramatically increased, due to the increased
transcription of S-phase genes (aberrant S-phase induction)
resulting from the action of the oncogenic HPV E7 protein.
The minichromosome maintenance (MCM) proteins
functionintheearlystagesofDNAreplicationthroughload-
ingoftheprereplicationcomplexontoDNAandfunctioning
as a helicase to help unwind the duplex DNA during de
novo synthesis of the duplicate DNA strand [26, 27]. Origin
licensing, which occurs before S phase in late mitosis and
early G1, involves the stable loading of the minichromosome
maintenance (MCM) complex comprising six replication
proteins—MCM2, MCM3, MCM4, MCM5, MCM6, and
MCM7 (termed MCM2-7)—onto DNA at replication ori-
gins. Expression of all six MCMs is seen throughout all
phases of the cell cycle and is downregulated following
exit from the cell cycle into quiescence, diﬀerentiation, or
senescence, thus they are a unique marker of cells with pro-
liferative capacity. Deregulation of MCM2-7 appears to be
an early event in multistep tumorigenesis, and many studies
have now shown that there is inappropriate expression of
MCM2-7 in a wide variety of premalignant dysplasias and
cancers [28–31].
Similar to the MCM2-7 markers, topoisomerase II-α
(TOP2A) has been shown to be overexpressed in cervical
neoplasia at both the mRNA and protein levels [32–35].
TOP2A is a nuclear enzyme that is responsible for relax-
ing supercoiled DNA during DNA replication and during
chromosome condensation and mitosis and is required for
the segregation of daughter chromosomes at the end of
replication. Evaluation of TOP2A expression has shown that
TOP2A overexpression is associated with the progression
from CIN2 to advanced cervical neoplasia [32].
The BD ProEx C test was designed as a reﬂex test
to identify CIN2+ disease in women with ASC-US and
LSIL cytology results. The next generation test designed for
primary screening applications, BD SurePath Plus, combines
ononeslidetraditionalPapstainingforcellularmorphology,
in combination with immunocytochemical detection of
the overexpression of two biomarkers: MCM2 and MCM7
(Figure 2).
2.4. Cytoactiv HPV L1 Capsid Protein. The Cytoactiv Screen-
ing antibody detects the L1 capsid protein of all known HPVJournal of Oncology 5
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Figure 3: Biomarker expression in cervical intraepithelial neoplasia. The proliferative compartment progressively expands with histological
grade, and this is paralleled by the appearance of immunostaining for Ki-67, p16INK4a, and BD ProEx C in more superﬁcial epithelial layers,
with the majority of the epithelium staining in high-grade squamous intraepithelial lesions. For Cytoactiv HPV L1, higher expression is
found in low-grade lesions, with a loss of L1 protein often observed in high-grade lesions (L1 images courtesy of Dr. Ralf Hilfrich).
types. Together with the L2 protein, the L1 capsid protein
forms a protective cover for the viral genetic material. In
addition, it is a ligand for a surface receptor of the host cell in
thebasal/parabasalcelllayeroftheepithelium,gainingaccess
to the basal epithelial layer as a result of epithelial erosions or
mucosal ulcerations in the transformation zone susceptible
to inﬂammation at the cervical/endocervical junction. HPV
L1 expression is found in the early, productive phase of
HPV infection but is progressively lost during cervical
carcinogenesis. This loss of L1 expression may result from
the integration of viral DNA into the human genome, which
may disrupt the L1 gene or cause loss of L1 expression by
segregating the viral promoter from the L1 gene, or may
reﬂect an abnormality in transcription factor pathways or in
control of L1 protein translation [36, 37].
As the L1 capsid protein is one of main targets for T cell-
mediated immune response, cells with a lack of L1 protein
synthesis may escape immune system recognition, allowing
disease progression. Promising data using the Cytoactiv test
(Cytoimmun, Pirmasens, Germany) supports this notion,
with progressive disease more frequently detected in L1-
negative intraepithelial lesions [38–41].
3. Role of Biomarkers to Improve Cervical
Cancer Screening
The use of biomarkers such as Ki-67, p16INK4a,a n dB D
ProEx C has been reported to facilitate the detection of
abnormal cells within a Pap cytology sample based upon
simple immunocytochemistry assay formats (Figure 2). The
published reports on the use of these biomarkers in Pap
cytology samples have indicated their ability to triage mildly
abnormal and indeterminate cytology cases, with those
found to have increased levels of biomarkers staining more
likelytorepresentcaseswithtruehigh-gradecervicaldisease.
In addition, the biomarkers can be utilized to highlight
potentially abnormal cells on a background of normal,
reactive or other nonmalignant cells, through colorimetric
staining, directing the attention of slide screeners to cells of
interest.
TheutilityofKi-67immunocytochemistryhasbothbeen
shown in conventional Pap smears [42–44] and liquid-based
cervicalcytology[45,46].InpatientswithASC-USandLSIL,
Ki-67 immunocytochemistry demonstrated 96% sensitivity,
67% speciﬁcity, 49% PPV, and 98% NPV for detection
of high-grade CIN [42]. Sahebali et al. [45] reported that
receiver operating characteristic curves indicated a test
accuracy (AUC) of 0.68, 0.72, and 0.86 for ASC-US, LSIL,
and HSIL, respectively.
A recent meta-analysis analyzed 27 studies evaluating the
use of p16INK4a immunostaining in cytological specimens
from the uterine cervix [24]. The proportion of cervical
smears overexpressing p16INK4a increased with the severity of
cytological abnormality, with 12% of normal smears positive
for the biomarker compared to 45% of ASC-US and LSIL,
and 89% of HSIL smears. In order to improve the speciﬁcity
of p16 cytology, an interpretation algorithm was developed
whichincorporatescomponentsofbothstainingandnuclear
score in order to facilitate the assessment of the biomarker
[47]. In an ASC-US/LSIL triage study, this scoring system
resulted in 95% sensitivity and 84% speciﬁcity for ASC-US
and 100% sensitivity and 82% speciﬁcity in LSIL for the
detection of biopsy-proven high-grade CIN [48].
In a subset of patients from the Technologies for Cervical
Cancer screening (NTCC) randomized controlled trial in
Italy, the performance of p16 triage of HPV primary
screen-positive women was examined [49]. Sensitivity and
speciﬁcity for CIN2+ and CIN3+ of p16 immunostaining
was 88% (95% CI 80–94) and 61% (633/1045; 57–64),
respectively, with CIN2+ as the endpoint, and 61% (95%
CI 77–97) and 59% (95% CI 55–63) for the CIN3+ end-
point, respectively. This screening algorithm was reported to
produce a signiﬁcant increase in sensitivity compared with6 Journal of Oncology
conventionalcytology,withnosubstantialincreaseinreferral
to colposcopy [39].
The CINTec Plus biomarker cocktail, composed of
antibodies against p16INK4a and Ki-67, has been evaluated
as a reﬂex test from borderline cytology results and in
cytology negative, high-risk HPV positive cases [50–52]. In
the European Equivocal or Mildly Abnormal Pap Cytology
Study (EEMAPS), the sensitivity of the dual stain cytology
for biopsy-conﬁrmed CIN2+ was 92.2% for ASC-US cases
and 94.2% for LSIL, with speciﬁcity of 80.6% and 68.0%,
respectively [50]. As a triage for HPV-positive, cytology-
negative cases in women ≥ 30, Petry et. al. [52]o b s e r v e da
91.9% sensitivity and 82.1% speciﬁcity for CIN2+ on biopsy.
The performance of BD ProEx C in the detection
of CIN2+ disease in ASC-US+ BD SurePath liquid-based
cytology specimens has been reported in ﬁve studies, with
sensitivity, speciﬁcity, PPV, and NPV for detection of CIN2+
disease ranging from 56.5–98%, 72-97.6%, 27.4–97%, and
95–99.3%, respectively [53–57]. A few studies have directly
compared the performance of p16INK4a [21, 23, 58]a n d
BD ProEx C [55, 56] immunocytochemistry to HPV DNA
detection by Hybrid Capture 2 (Qiagen, Venlo, The Nether-
lands) for the detection of CIN2+ disease. The PPV of
both biomarkers was found to be superior to HC2 in these
studies, which analyzed ASC-US, LSIL, and ASC-H liquid-
based cytology specimens. Depuydt et al. [57] evaluated the
eﬃcacy of eight cervical cancer screening strategies relative
to cytology with emphasis on the use of the BD ProEx C
biomarker as a tool of triage following primary cytology or
hrHPV testing. In the context of a reﬂex application from a
high-risk HPV primary screen to identify CIN2+ disease, BD
ProEx C was found to increase the speciﬁcity (98.3% versus
85.0%)andPPV(41.7%versus9.3%)ofscreeningcompared
to hrHPV alone, resulting in an 82% decrease in colposcopy
procedures.
4. Improvement in the Histological
Classiﬁcationof CervicalBiopsies
Whilethecytology-basedPaptestisusedasthescreeningtest
for cervical cancer, histopathological evaluation of a cervical
biopsy from a woman with an abnormal Pap test is the “gold
standard” for the diagnosis of cervical neoplasia. However,
diagnosis variability has been documented among observers
and depends, in part, on the grade of the abnormality
[59]. Previous studies have demonstrated that the histologic
detection and grading of HPV-induced CIN, especially the
low-grade categories such as atypical squamous metaplasia,
HPV koilocytosis, and CIN1, have poor reproducibility
and are limited by interobserver variability [60, 61]. As
reactive/reparative epithelial changes, immature squamous
metaplasia and atrophy are well-recognized mimics of high-
grade disease and frequently cause problems in histological
interpretation, there is a need in pathology practice for
a biomarker reagent that will help in distinguishing true
dysplasia from dysplasia mimics. The ability to make this
distinction will ensure that invasive procedures, such as
LEEP and cone biopsy, which can result in pregnancy
complications in future pregnancies, are only performed on
women with true high-grade cervical disease.
It has been shown that Ki-67, p16INK4a,a n dB DP r o E x
C immunostains are helpful in the assessment of cervical
biopsies by decreasing interreader variability, assisting in
the discrimination of true dysplasia from mimics, and
identifying regions of focal disease that can be missed with
H & E staining alone. Representative staining patterns of the
biomarkersincervicaldysplasiaareshowninFigure 3.While
a nuclear staining pattern is observed with the Ki-67 and BD
ProEx C biomarkers, the p16INK4a staining pattern is more
variable, with staining found in the nucleus, cytoplasm, or
both, the signiﬁcance of which is not fully understood at the
present time.
The performance of Ki-67 [16, 42, 67], p16INK4a
(reviewed in [24] ) ,a n dB DP r o E xC[ 62–64, 66, 68–72]i n
histological applications has been evaluated in many studies.
The comparison of biomarker performance in the detection
of high-grade cervical disease is diﬃcult due to the vari-
ability in specimens, study design, antibodies, and scoring
algorithms utilized. A limited number of studies, however,
have analyzed the performance of Ki-67, p16INK4a,a n dB D
ProEx C immunohistochemistry on the same sample sets,
allowing a preliminary comparison to be made, although
scoring algorithms are inconsistent [62–66]( Table 2). The
performance of the three biomarkers was fairly comparable,
with BD ProEx C and p16INK4a tending to have better
diagnostic value than Ki-67. Two studies suggest that BD
ProEx C has improved eﬃcacy in the detection of low-
grade lesions [62, 63]. Of the three studies using histological
tissue [62–64], each concludes that the BD ProEx C/p16INK4a
biomarker combination appears to have the best overall
performance for triaging diagnostically diﬃcult atypias in
which the diﬀerential diagnosis includes HSIL, and for the
detection of clinically relevant disease compared with the
single biomarkers or other biomarker combinations.
Negrietal.[68]evaluatedtheutilityofp16INK4a,ProExC,
and Ki-67 for the diagnosis of endocervical adenocarcinoma
and its precursors. p16INK4a was at least focally expressed
in 93% (14/15) of invasive adenocarcinomas, 100% of AIS
(29/29), and 32% (7/22) negative samples. ProEx C and Ki-
67 both scored positive in all adenocarcinomas (15/15) and
AIS (29/29), and in 36% (8/22) and 27% (6/22) of negative
samples, respectively. p16 and Ki-67 individually stained
positive in 94% (15/16) of glandular dysplasia cases, with
87.5% positivity (14/16) detected with ProEx C. The score
diﬀerences between neoplastic and nonneoplastic samples
were highly signiﬁcant for each marker (P<0.001), and
each biomarker was shown to be useful for the diagnosis
of neoplastic lesions of the glandular epithelial of the cervix
uteri.
In a study examining cell block preparations [65],
BD ProEx C was found to have a higher PPV for high-
grade dysplasia/carcinoma (89%) than p16 (50%), with a
NPV value of 93% for ProEx C compared with 100% for
p16INK4a. The study concluded that BD ProEx C had a
better overall performance in diﬀerentiating NILM versus
HSIL/SCC compared with p16INK4a with the added beneﬁt
of having clean nuclear staining.Journal of Oncology 7
Table 2: Biomarker positivity by histological grade of cervical intraepithelial lesion.
Study Biomarker WNL CIN1 CIN2+
Ki-67 2/14 (14%) 29/34 (85%) 14/14 (100%)
Shi 2007 et al. [62]p 1 6 INK4a 0/14 (0%) 26/34 (77%) 14/14 (100%)
BD ProEx C 0/14 (0%) 32/34 (94%) 11/14 (79%)
BD ProEx C/p16 0/14 (0%) 34/34 (100%) 14/14 (100%)
Ki-67 0/37 (0%) 6/22 (27%) 34/37 (91%)
Badr 2008 et al. [63]p 1 6 INK4a 2/38 (5%)∗ 8/23 (35%)∗∗ 35/37 (93%)
BD ProEx C 1/38 (3%) 11/23 (48%) 34/37 (92%)
BD ProEx C/p16 3/35 (9%) 15/23 (65%) 37/37 (100%)
Ki-67 11/23 (48%) ND 34/36 (94%)
Pinto 2008 et al. [64]p 1 6 INK4a 13/35 (37%) ND 51/61 (84%)
BD ProEx C 10/35 (29%) ND 52/60 (87%)
BD ProEx C/p16 9/23 (39%) ND 33/36 (92%)
Ki-67 14/29 (48%)a 22/27 (82%) 15/16 (94%)
Halloush 2008 et al. [65]p 1 6 INK4a 19/29 (66%)b 25/27 (92%) 19/19 (100%)
BD ProEx C 2/29 (7%)c 2/27 (7%) 16/19 (84%)
Ki-67 6/26 (23%) 10/21 (48%) 76/85 (89%)
Conesa-Zamora 2009 et al.
[66] p16INK4a 4/28 (14%) 12/19 (63%) 74/85 (87%)
BD ProEx C 3/25 (12%) 10/19 (53%) 70/80 (88%)
WNL: within normal limits; CIN: cervical intraepitelial neoplasia; ND: not determined; ∗Spotty staining; ∗∗5/23 spotty staining; a12/29 <1% staining, 2/29
≥1% staining; b19/29 <10% staining; c1/29 <10%.
5. Evaluation of Progression Risk
One major issue in the management of cervical cancer is the
evaluation of progression risk of dysplastic lesions. Patients
with CIN1 must be periodically followed due to the risk
of progression to high-grade lesions or carcinoma. As 70–
80% of low-grade lesions spontaneously regress and not all
high-grade lesions progress [73], some women may undergo
unnecessarytreatmentorhaveadelayinreceivingtreatment.
Thus, the identiﬁcation of biomarkers to select women
t r u l ya tr i s ko fl e s i o np r o g r e s s i o na n di nn e e do ft r e a t m e n t
could lead to tremendous cost savings and eliminate patient
anxiety.
A limited number of studies have reported that the
application of Ki-67 immunoquantitative analyses of CIN1
and CIN2 can predict disease progression, with the best
features to predict progression being the 90th percentile of
the stratiﬁcation index and the percentage of Ki-67 positive
cells in the middle third layer of the epithelium [74, 75].
Recent prospective end point studies have shown that
p16INK4a positive low-grade lesions have a higher risk of
progression than negative lesions, although this correlation
was certainly not absolute [76–79]. Additional prospective
data are necessary, however, to conﬁrm this association.
Ozaki et al. [80] examined expression of the p16INK4a and
ProEx C biomarkers in premalignant lesions to determine
which markers could help in prediction of the progression
of CIN1. Expression of both markers was signiﬁcantly higher
in the progression group compared to the regression group,
being sensitive (86%) and moderately speciﬁc (60% and
61%, resp.) in predicting CIN1 progression. Hariri and
Hansen [81] compared the prognostic value of p16INK4a to
BD ProEx C and HPV ISH in CIN1 cases and found BD
ProEx C to be a reliable marker for prediction of 6-year
outcome, with an NPV of 95.3% compared with 88.6% for
p16 and 87.5% for HPV ISH and a PPV of 51% compared
with 40.4% and 67.9%, for p16 and HPV ISH, respectively.
Interestingly, CIN2/3 cervical histology specimens have
been described with very strong p16INK4a positivity, but
only very focal Ki-67 staining, indicating a presence of
a small subset of HSILs with low proliferative activity
[82, 83]. Cases like this may represent the ﬁrst stages of HSIL
regression.
HPV L1 is a capsidic protein that is expressed in the
early, productive phase of HPV infection, but progressively
lost during cervical carcinogenesis. An analysis of thin-
layer preparations showed that the L1 capsid protein is
produced in about 80% of mild-to-moderate dysplasias,
whereas it could only be detected in about 25% of higher-
grade dysplasias using immunological methods [28], due, in
part, to HPV integration that accompanies the development
of cervical neoplasia. The detection of the HPV L1 capsid
protein in combination with p16INK4a, to conﬁrm the
associationofthelesionwithHPV,hasbeenreportedtoserve
asaprognosticmarkerthatcandiﬀerentiatebetweenpatients
who will undergo a transition from a precursor lesion to
cancer and those whose lesions will regress [39, 84]. While
the data is still preliminary, in cases where the grade of
lesion is morphologically diﬃcult to assess, the L1 pattern
may be helpful for deciding the appropriate management
of women. L1-negative HPV high-risk positive mild and
moderatelesionshaveanextremelylowprobabilitytoregress8 Journal of Oncology
spontaneously (5%) in contrast to the L1 positive cases
showing a low malignant potential [41].
6. Summary
A number of protein biomarkers are currently available
to assist in improving the clinical performance of cervical
cancer screening. The recent introduction of prophylactic
HPV vaccines will eventually reduce the incidence of cervical
cancers and its malignant precursors, therefore, increase the
importance of biomarkers in future cervical cancer screening
programs to identify for treatment only those women truly
at high risk for developing cervical cancer. It is anticipated
that the use of these biomarkers can be applied both as
a reﬂex test from an atypical Pap specimen but also as a
primary screen to improve the overall accuracy of the Pap
test. The introduction of HPV primary screening programs
will necessitate the use of a reﬂex test with high speciﬁcity
to triage the high number of HPV positive tests. It is
believed that biomarkers will also serve an important role
in the optimization of this alternative screening algorithm.
Current translational research investigations are continuing
to discover, characterize, and validate such biomarkers for
these anticipated applications.
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